Aberrant signaling pathways in squamous cell lung carcinoma

Cancer Informatics

Volumn 10, Issue , 2011, Pages 273-285

  Shi, Ivy ^a,b   Sadraei, Nooshin Hashemi ^c   Duan, Zhong Hui ^d,e   Shi, Ting ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Hudson High School   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d The University of Akron   (United States)

^e UNIVERSITY OF AKRON   (United States)

Author keywords

Biomarkers; Cancer treatment; Drug targets; Microarray technology; Non small cell lung cancer; Signaling pathways

Indexed keywords

BETA CATENIN; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR; ERLOTINIB; GANT 61; GEFITINIB; INTERLEUKIN 8; KERATIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN INHIBITOR; PROTEIN P53; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CELL CYCLE REGULATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC REGULATION; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 83455234736     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S8283     Document Type: Article

References (58)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Web. October 21, 2010. http://globocan.iarc.fr.
2. American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010. Web. October 21, 2010. http://www.cancer.org/ research/cancerfactsfigures/cancerfactsfigures/cancer-facts-and-figures-2010.
3. Lung Cancer (non-small cell) Overview. American Cancer Society, October 6 2010. Web. October 21, 2010. http://www.cancer.org/Cancer/ LungCancer-Non-SmallCell/OverviewGuide/index.
4. Non-Small Cell Lung Cancer Treatment. National Cancer Institute, October 6 2010. Web. October 21, 2010. http://www.cancer.gov/ cancertopics/pdq/treatment/non-small-cell-lung/Patient/.
5. Cancer Genetics Overview. National Cancer Institute, October 6, 2010. Web. October 21, 2010. http://www.cancer.gov/cancertopics/pdq/genetics/ overview/healthprofessional/.
6. Pierre P, Massion, David, P Carbone. The molecular basis of lung cancer: molecular abnormalities and therapeutic implications, Respir Res. 2003; 4(1):12.
7. Schena M, Shalon D, Davis RW, Brown PO. Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray. Science. 270:467-70;1995.
8. DeRisi J, Penland L, Brown P, et al. Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer. Nature Genetics. 1996;14: 457-60.
9. Golub TR, Slonim DK, Tamayo P, et al. Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring. Science. 1999;286:531-7.
10. Sathyamangla V, Naga Prasad, Zhong-Hui Duan, et al. Unique MicroRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem. 2009;284(40):27487-99.
11. Louis SL, Ting Shi, Zhong-Hui Duan, et al. Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urology. 2004;4:9.
12. Ting Shi, Louis SL, Provash Sadhukhan, et al. Effects of resveratrol on gene expression in renal cell carcinoma. Cancer Biol Ther. 2004;3(9): 882-8.
13. Kim Y H, Girard L, Giacomini C P, et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene. 2006; 25(1):130-8.
14. Arindam Bhattacharjee, William GR, Jane Staunton, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci. 2001;98(24):13790-5.
15. Shinichiro Wachi, Ken Yoneda, Reen Wu. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics. 2005;21(23):4205-8.
16. Abel Sanchez-Palencia, Mercedes Gomez-Morales, Jose Antonio Gomez-Capilla, et al. Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. International Journal of Cancer. 2011;129(2):355-64.
17. Roxy Peck, Chris Olsen, Jay L. Devore, Introduction to Statistics and Data Analysis, 3rd edition, Duxbury Press, 2007.
18. Yoav Benjamini, Yosef Hochberg. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Methodological). 1995;57 (1):289-300.
19. John DS, Robert Tibshirani. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100(16):9440-5.
20. Fisher's Exact Test. Wolfram Math World. Web. 27 Dec. 2010. http:// mathworld.wolfram.com/FishersExactTest.html.
21. Yan Zhang, Daniel Kalderon, Hedgehog acts as a somatic stem cell factor in the Drosophila ovary. Nature. 2001;410(6828):599-604.
22. Lawrence Lum, Philip AB. The Hedgehog response network: sensors, switches, and routers. Science. 2004;304(5678):1755-9.
23. Seyun Kim, Pauline Wong, Pierre A, Coulombe. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature. 2006; 441(7091):362-5.
24. Jürgen Schweizer, Paul EB, Pierre AC, et al. New consensus nomenclature for mammalian keratins. Journal of Cell Biology. 2006;174:169-74.
25. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2011;30(2):127-38.
26. George RS, William R. Taylor. Analyzing the G2/M checkpoint. Methods Mol Biol. 2004;280:51-82.
27. Eiman Aleem, Hiroaki Kiyokawa, Philipp Kaldis. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol. 2005;7(8):831-6.
28. Philipp Kaldis, Eiman Aleem. Cell cycle sibling rivalry: Cdc2 vs. Cdk2. Cell Cycle. 2005;4(11):1491-4.
29. Dawid IB, Breen JJ, Toyama R. LIM domains: multiple roles as adapters and functional modifiers in protein interactions, Trends Genet. 1998;14(4): 156-62.
30. Chang Niu, Chaoyang Liang, Juntang Guo, et al. Downregulation and growth inhibitory role of FHL1 in lung cancer. Int J Cancer. Epub ahead of print, June 23, 2011. doi: 10.1002/ijc.26259.
31. Mellor H, Flynn P, Nobes CD, Hall A, Parker PJ. PRK1 is targeted to endosomes by the small GTPase, RhoB. J Biol Chem. 1998;273(9):4811-4.
32. Gampel A, Parker PJ, Mellor H. Regulation of epidermal growth factor receptor traffic by the small GTPase rhoB. Curr Biol. 1999;9(17):955-8.
33. Matthew Wherlock, Alexandra Gampel, Clare Futter, Harry Mellor. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J Cell Sci. 2004;117(Pt 15):3221-31.
34. Shi HY, Zhang W, Liang R, et al. Modeling human breast cancer metastasis in mice: maspin as a paradigm. Histol Histopathol. 2003;18(1):201-6.
35. Shaji Abraham, Weiguo Zhang, Norman Greenberg, Ming Zhang. Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. J Urol. 2003;169(3):1157-61.
36. Chengen Xu, Ruhul Quddus M, James Sung C, Margaret MS, Cunxian Zhang W. Dwayne Lawrence, Maspin expression in CIN 3, microinvasive squamous cell carcinoma, and invasive squamous cell carcinoma of the uterine cervix. Mod Pathol. 2005;18(8):1102-6.
37. Maass N, Hojo T, Ueding M, et al. Expression of the tumor suppressor gene Maspin in human pancreatic cancers, Clin Cancer Res. 2001;7(4): 812-7.
38. Gabriel JV, Maya Zigler, Andrey SD, et al. Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype, Proc Natl Acad Sci U S A. 2011;108(2):626-31.
39. Au NHC, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004;12(3):240-7.
40. Nicola Normanno, Antonella De Luca, Caterina Bianco, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16.
41. David MJ, Vincent AM, Leigh-Anne Cioffredi, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009;15(16):5267-73.
42. Noemí Reguart, Andrés Felipe Cardona, Rafael Rosell. Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. Cancer Manag Res. 2010;2:143-56.
43. Kenji Takeuchi, Fumiaki Ito. EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J. 2010;277(2):316-26.
44. Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New England Journal of Medicine. 2010;362(25):2380-8.
45. Christopher D, Coldren, Barbara A, et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 2006;4(8):521-8.
46. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-39.
47. Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008;14(15):4877-82.
48. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med. 2005;353(2):123-32.
49. Alexandra Klaus, Walter Birchmeier. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387-98.
50. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001;411(6835):349-54.
51. Matthias Lauth, Åsa Bergström, Takashi Shimokawa, Rune Toftgård. Inhibition of GLI-mediated transcription and tumor cell growth by smallmolecule antagonists. Proc Natl Acad Sci. 2007;104(20):8455-60.
52. Hudes G, Carducci M, Tomczak P, et al. Global ARCC Trial, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-81.
53. Motzer RJ, Escudier B, Oudard S, et al. RECORD-1 Study Group, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-56.
54. Neil Watkins D, David M, Berman, et al. Hedgehog signaling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003; 422(6929):313-7.
55. Pilar Sanchez, Ana Maria Hernández, Barbara Stecca, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOGGLI1 signaling. Proc Natl Acad Sci. 2004;101(34):12561-6.
56. Lee L, Rubin, Frederic J de Sauvage. Targeting the Hedgehog pathway in cancer. Nature Reviews Drug Discovery. 2006;5(12):1026-33.
57. Ting Shi, Tapati Mazumdar, Jennifer DeVecchio, et al. cDNA microarray gene expression profiling of hedgehog signaling pathway inhibition in human colon cancer cells. PLoS One. 2010;5(10).
58. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24): 2542-50.